PD-1 Blockade in Anaplastic Thyroid Carcinoma
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia)
Wirth, Lori J. (Harvard Medical School)
Ernst, Thomas (Universitätsklinikum Jena)
Ponce Aix, Santiago (Hospital Universitario 12 de Octubre (Madrid))
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan))
Ramlau, Rodryg (Poznań University of Medical Sciences)
Butler, Marcus O. (Princess Margaret Cancer Centre)
Delord, Jean-Pierre (IUCT Oncopole)
Gelderblom, Hans J (Leiden University Medical Center)
Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G. Pascale)
Fasolo, Angelica (San Raffaele Hospital)
Führer, Dagmar (University Hospital Essen (Alemanya))
Hütter-Krönke, Marie Luise (University Hospital of Ulm (Alemanya))
Forde, Patrick M. (Sidney Kimmel Comprehensive Cancer Center)
Wrona, Anna (Uniwersyteckie Centrum Kliniczne)
Santoro, Armando (IRCCS Humanitas University)
Sadow, Peter M. (Harvard Medical School)
Szpakowski, Sebastian (Novartis Institutes for BioMedical Research)
Wu, Hongqian (Novartis Pharmaceuticals)
Bostel, Geraldine (Novartis Institutes for BioMedical Research)
Faris, Jason (Novartis Institutes for BioMedical Research)
Cameron, Scott (Novartis Institutes for BioMedical Research)
Varga, Andreea (Gustave Roussy Cancer Campus)
Taylor, Matthew (Oregon Health & Science University)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF -wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor. We enrolled patients with locally advanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the study. Patients received 400 mg spartalizumab intravenously, once every 4 weeks. The overall response rate was determined according to RECIST v1. 1. Forty-two patients were enrolled. Adverse events were consistent with those previously observed with PD-1 blockade. Most common treatment-related adverse events were diarrhea (12%), pruritus (12%), fatigue (7%), and pyrexia (7%). The overall response rate was 19%, including three patients with a complete response and five with a partial response. Most patients had baseline tumor biopsies positive for PD-L1 expression (n = 28/40 evaluable), and response rates were higher in PD-L1-positive (8/28; 29%) versus PD-L1-negative (0/12; 0%) patients. The highest rate of response was observed in the subset of patients with PD-L1 ≥ 50% (6/17; 35%). Responses were seen in both BRAF -nonmutant and BRAF -mutant patients and were durable, with a 1-year survival of 52. 1% in the PD-L1-positive population. To our knowledge, this is the first clinical trial to show responsiveness of anaplastic thyroid carcinoma to PD-1 blockade.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Estudi clínic ; recerca ; Versió publicada
Publicat a:	Journal of Clinical Oncology, Vol. 38 Núm. 23 (may 2020) , p. 2620-2627, ISSN 1527-7755

DOI: 10.1200/JCO.19.02727
PMID: 32364844

9 p, 801.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats